[Form 4] Thermo Fisher Scientific, Inc. Insider Trading Activity
Rhea-AI Filing Summary
Thermo Fisher (TMO) Form 4 — insider dispositions by Sr. VP & CFO Stephen Williamson. The filing reports four open-market sales on 08/28/2025 totaling 783.273 shares at $489.74 per share. After these transactions, Williamson directly held 32,320.193 shares and is noted as indirectly beneficially owning 12,674 shares through a SLAT, with a disclaimer that he disclaims beneficial ownership except for any pecuniary interest. The form is signed by an attorney-in-fact on 09/02/2025.
Positive
- None.
Negative
- Insider dispositions: Four sales totaling 783.273 shares on 08/28/2025 at $489.74 per share.
- Reduction in direct holdings: Direct holdings reported decreased to 32,320.193 shares after the transactions.
Insights
TL;DR: CFO sold 783.273 shares at $489.74, reducing direct holdings modestly; transaction size appears routine for an executive.
The filing documents four separate dispositions on a single date totaling 783.273 shares at $489.74 each. Proceeds can be computed from these explicit amounts; the transactions reduced the reporting person’s direct holdings from 32,888.792 to 32,320.193 shares as shown. No option exercises, grants, or derivative transactions are reported. This is a clear disclosure of insider selling without additional context about purpose or a 10b5-1 plan on the face of the form.
TL;DR: Multiple same-day dispositions by the CFO warrant governance attention but are disclosed per Section 16 requirements.
The report meets Section 16 disclosure standards by listing each disposition and the post-transaction beneficial ownership, and it includes the required signature by an attorney-in-fact. The filing also includes an explicit disclaimer of indirect beneficial ownership and identifies the SLAT holding 12,674 shares. Absent additional information (e.g., a stated 10b5-1 plan), governance teams may note timing but cannot infer intent solely from this disclosure.